The University of Cape Town (UCT)’s Drug Discovery and Development Centre, H3D, has identified a new potent anti-malarial development candidate with potential for both treatment and prevention of malaria
Maison de la Paix, Chemin Eugène-Rigot 2, 1202 Geneva
Please join us at this year’s World Health Assembly for a conversation with product developers on developing and scaling essential
health technologies. This moderated panel discussion will explore the current challenges of incentivising the development of innovative technologies that address the burden of disease globally, specifically poverty related and neglected diseases, while ensuring they are accessible to those most in need. Representatives from industry, academia, and nonprofit product development partnerships will debate the most significant barriers to access, and share successes, challenges, and lessons learned from a product developer’s perspective.
The University of Cape Town’s Drug Discovery and Development Centre, H3D, has entered into a strategic partnership with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), aimed at jointly identifying and addressing the unique issues of advanced drug development in Africa.
The Universities of Dundee (Scotland) and Cape Town (South Africa) have linked up with the industrial expertise of the pharmaceuticals division of Germany’s Bayer (BAYN: DE), in an effort to develop critically needed new treatments for tuberculosis (TB). The collaboration combines some of the world’s best knowledge on TB biology, drug discovery and medicinal chemistry, with access to an industrial library of chemical compounds.